SDMA

Overview

SDMA, also known as 3,4-methylenethiooxy-N-methylamphetamine (3T-MDMA) or as MY100, is a putative entactogen of the phenethylamine and amphetamine families related to 3,4-methylenedioxy-N-methylamphetamine (MDMA). It is the analogue of MDMA in which the oxygen atom at the 3 position within the 3,4-methylenedioxy substitution has been replaced with a sulfur atom to give a 1,3-benzoxathiole rather than 1,3-benzodioxole ring system. The drug is also the N-methyl derivative of 3,4-methylenethiooxyamphetamine (SDA; 3T-MDA). SDMA is of interest for potential therapeutic use.[1][2] WP

Pharmacology

Pharmacodynamics

Similarly to MDMA, SDMA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA) and a non-selective serotonin 5-HT₂ receptor agonist. However, SDMA was 11-fold more potent as a serotonin releaser, 19-fold more potent as a dopamine releaser, and 2-fold more potent as a norepinephrine releaser than MDMA in HEK293 cells in vitro. In addition, it was about twice as potent as a serotonin 5-HT2A receptor agonist, whereas it showed similar agonistic potency as MDMA at the serotonin 5-HT2B and 5-HT2C receptors. SDMA had similar activational efficacies at the serotonin 5-HT₂ receptors as MDMA. Due to its greater potency as a monoamine releasing agent, SDMA may be active at lower doses or concentrations than MDMA.[1] WP

SDMA produced hyperlocomotion and hyperthermia in rodents with similar profiles as MDMA. However, SDMA did not produce rewarding effects in the conditioned place preference (CPP) paradigm unlike MDMA. Hence, SDMA might have reduced misuse potential compared to MDMA. As with MDMA, SDMA did not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence may not produce hallucinogenic effects in humans. SDMA might be less cardiotoxic than MDMA due to having much greater monoamine-releasing potency but unaltered serotonin 5-HT2B receptor agonistic potency.[1] WP

Pharmacokinetics

The metabolism and metabolites of SDMA have been studied. It showed more rapid clearance than MDMA in rodents and hence may have a shorter elimination half-life and/or duration.[1] WP

History

History

SDMA was first mentioned in the scientific literature by 2013, but was only conceptually described at this time. Subsequently, its synthesis and preclinical pharmacology were described by Nina Kastner and colleagues including Matthias Grill at MiHKAL in 2025. In addition, SDMA was patented by Mydecine as a shorter-acting MDMA alternative in 2023. Prodrugs of SDMA and/or related compounds have also been described. The drug is of interest for potential therapeutic use, for instance treatment of post-traumatic stress disorder (PTSD).[1–8] WP

Chemistry

Formula

C11H15NOS PC

Molar mass (g/mol)

209.31 PC

IUPAC name (computed by PubChem)

1-(1,3-benzoxathiol-5-yl)-N-methylpropan-2-amine PC

SMILES

CC(CC1=CC2=C(C=C1)OCS2)NC PC

InChIKey

FCMBKJAWTSTFFR-UHFFFAOYSA-N PC

PubChem CID

169291098

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Kastner N, Nadal-Gratacós N, Hemmer S, Alves da Silva L, McKee JL, Hell T, Cicalese G, Holy M, Kooti F, Jäntsch K, Baron R, Shacham N, Cuccurazzu B, Halberstadt AL, McCorvy JD, Stockner T, Meyer MR, López-Arnau R, Grill M, Sitte HH. Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights. ACS Chemical Neuroscience. December 2025. doi:10.1021/acschemneuro.5c00782 · PMID 41329099 · PMC12715756
2. Journal / agency Sáez-Briones P, Hernández A. MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology. Current Neuropharmacology. September 2013. doi:10.2174/1570159X11311050007 · PMID 24403876 · PMC3763760
3. Other Prodrug compounds of 3,4-methylenedioxymethamphetamine (MDMA) and methods of synthesizing the same
4. Other Short-acting psychoactive compounds of the MDMA class
5. Other Novel short-acting psychoactive compounds of the MDMA class
6. Other Novel short-acting psychoactive compounds of the MDMA class
7. Other Novel short-acting psychoactive compounds of the MDMA class
8. Other WIPO - Search International and National Patent Collections

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.